UCL Technology Fund

The UCL Technology Fund (UCLTF) is a venture capital fund established in 2016 to commercialize cutting-edge research originating from University College London (UCL). Managed in partnership with AlbionVC and UCL Business, the fund focuses on investing in intellectual property arising from UCL's research in life sciences, physical sciences, and engineering. UCLTF plays a pivotal role in taking groundbreaking technologies from early-stage proof of concept through to commercialization, either via licensing or by forming spinout companies. With an emphasis on life sciences, the fund supports pioneering projects in areas such as gene therapy, oncology, and advanced materials. Notable investments include Orchard Therapeutics, a spinout specializing in rare disease gene therapies, and Bloomsbury AI, which developed natural language processing technology before being acquired by Facebook in 2018. The fund's portfolio is diverse, encompassing companies tackling global challenges like clean energy through firms such as Carbon Re, which is focused on decarbonizing heavy industries​. The fund’s mission is not only to support UCL's world-class academic research but also to deliver societal impact and substantial commercial returns. The first fund has seen impressive successes, including two Nasdaq IPOs and raising over £1 billion in external funding across its portfolio. Recently, UCLTF closed its second fund at £100 million, further strengthening its ability to back high-impact innovations in biotech, healthcare, and AI.